Affymax (AFFY +0.9%) rebounds from early morning weakness after the company disclosed in a...

|By:, SA News Editor

Affymax (AFFY +0.9%) rebounds from early morning weakness after the company disclosed in a regulatory filing that it has entered into a fourth amendment to its collaboration and license agreements with Takeda Pharmaceutical. The amendment, which is a part of the company's ongoing restructuring efforts, changes the economics from a profit-sharing arrangement to a milestone and royalty-based compensation structure, and stems from the voluntary recall and FDA suspension related to Omontys.